Significant differences in clinical response and inflammation (using Pediatric Crohn Disease Activity Index (PCDAI) and CRP values) was also found at week 12 between the two groups, showing how a PEN, if associated with dietary therapy, can better improve both symptoms and remission (PCDAI <10 achieved by 75.6% of patients on CDED + PEN vs. 45.1% of EEN ones, p = 0.01; Normal CRP occurred in 75.9% of patients on CDED + PEN vs. 47.6% of EEN ones, p = 0.04). This evidence concerns the gene CRP and Crohn disease.